Six institutions waiting to become part of PLACID trial

At a time when Kerala is expecting a fresh wave of Covid-19 transmission, six health institutions have applied for the convalescent plasma therapy trials. 

Published: 10th May 2020 06:33 AM  |   Last Updated: 10th May 2020 06:33 AM   |  A+A-

Express News Service

THIRUVANANTHAPURAM: At a time when Kerala is expecting a fresh wave of Covid-19 transmission, six health institutions have applied for the convalescent plasma therapy trials. The institutions include four in public sector and two in private sector. According to the health department,   applications submitted by these institutions are under active consideration of the Indian Council of Medical Research (ICMR) and a decision is expected soon. Under convalescent plasma treatment, antibodies from the blood of those who fought off SARS-CoV-2 will be isolated and injected into a patient who is infected. It is expected that the antibodies will stimulate the sick patient’s immune system to better fight the disease.

The institutions which have applied from the state for becoming a part of the convalescent plasma therapy trial, more commonly known as the PLACID trial, are Thiruvananthapuram and Kozhikode medical colleges, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Malabar Cancer Centre, Amrita Institute of Medical Sciences and Research Centre, Kochi, and Baby Memorial Hospital, Kozhikode.

“The PLACID trial is a multi-centre clinical trial initiated by the ICMR. The sample size of the study is 452. Earlier, ICMR had invited expression of interest from centres capable of undertaking the study. Though 113 institutions responded, ICMR on Friday approved 28 institutions for the PLACID trial,” said an official of the health department.According to the official, though not a single institution from Kerala figures in the approved list, six of them have been included in the consideration list.

According to ICMR, as it is considered that the use of convalescent plasma will improve the clinical outcomes in patients with moderate Covid-19 infection, a random controlled trial is needed to assess its efficacy and safety. The participation of patients will be based on written consent.Meanwhile, it is pointed out that the state’s chance for getting approval for a clinical trial is limited as the number of active cases went down drastically. Though the state reported over 500 positive cases of Covid-19, it registered a recovery rate of around 94 per cent.

More from Kerala.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp